CVR 44308266Private limited company (ApS)Fremstilling af farmaceutiske præparater (212000)København NFounded 14 Sep 2023
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about Combotope Therapeutics ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
5
CVR, Aug 2026
+2 (+66.7%) over 12 months
Gross profit
-633.4K
DKK, annual report 2025
Result
-934.4K
DKK, annual report 2025
Equity
1.1M
DKK, annual report 2025
Kolab Holding ApSCVR 44234882, 50% to under 66.7% of capital and votes
MOLIOR HOLDING ApSCVR 35257918, 33.3% to under 50% of capital and votes
Operating company
Dandex estimate: 5 employees registered in 2026Søren Nyboe Jakobsensince 14 Sep 2023
Klas Ola Blixtsince 14 Sep 2023
Owners of 5% or more. CVR registers shares in bands, not exact figures.
CVR 3525791833.3% to under 50% of capital and votesnotified 18 Nov 2024since 14 Sep 2023
CVR 4423488250% to under 66.7% of capital and votesnotified 26 Jun 2024since 14 Sep 2023
Ultimate controller
Holding in Kolab Holding ApS, since 14 Aug 2023
Holding company
CVR 44234882Private limited company (ApS)
Holding in Combotope Therapeutics ApS, since 14 Sep 2023
This company
Combotope Therapeutics ApS
CVR 44308266
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
Founded 14 Sep 2023.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
Aug 2026, monthly: 5 employees, 3 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | Dec 2023 | Jan 2024 | Feb 2024 | Mar 2024 | Apr 2024 | May 2024 | Jun 2024 | Jul 2024 | Aug 2024 | Sep 2024 | Oct 2024 | Nov 2024 | Dec 2024 | Jan 2025 | Feb 2025 | Mar 2025 | Apr 2025 | May 2025 | Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Apr 2026 | May 2026 | Jun 2026 | Jul 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 1 | 2 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 5 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 5 |
| FTE | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 |
| Series | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group.
Source: CVR, latest Aug 2026, published 21 Oct 2026.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2025, DKK: Gross profit -633.4K, Operating profit -1.2M, Result for the year -934.4K
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2025, DKK: Total assets 1.1M, Equity 1.1M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2024 | 2025 |
|---|---|---|
| Gross profit | -2,060 | -633 |
| Operating profit | -2,803 | -1,198 |
| Result for the year | -2,185 | -934 |
| Equity | 1,355 | 1,070 |
| Total assets | 1,381 | 1,089 |
| Employees (average) | 1 | 1 |
| Credit metrics (Dandex calculations) | ||
| EBITDA | -2,793 | -1,182 |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | |
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | |
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | |
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | |
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | |
| Capex (investeringer i anlægsaktiver) | Not reportednote 1 | 0note 2 |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | |
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | |
Not every period is a full year: 2024 covers 16 months (14 Sep 2023 to 31 Dec 2024). Changes against it compare periods of different length.
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
How each credit metric is calculated:
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for Combotope Therapeutics ApS:
Have Pro? Sign in.
Amounts in DKK. Cash price is per DKK 1 of nominal capital, which a share split does not move. Implied value is the whole capital after the step at its cash price, not a valuation.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseCashPaid in 150,000, cash price 75.00, implied value 4,747,500 | 75.00 | 150,000 | 4,747,500 | 63,300 | |
| IncreaseCashPaid in 500,000, cash price 83.33, implied value 5,108,331 | 83.33 | 500,000 | 5,108,331 | 61,300 | |
| IncreaseCashPaid in 500,000, cash price 142.86, implied value 7,899,998 | 142.86 | 500,000 | 7,899,998 | 55,300 | |
| IncreaseCashPaid in 1,000,000, cash price 161.29, implied value 8,354,838 | 161.29 | 1,000,000 | 8,354,838 | 51,800 | |
| IncreaseCashPaid in 2,000,000, cash price 357.14, implied value 16,285,716 | 357.14 | 2,000,000 | 16,285,716 | 45,600 | |
| FoundingCashPaid in 40,000 | None | 40,000 | None | 40,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Source: CVR, read 19 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 19 Nov 2026.
8 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Ny adresse: Ole Maaløes Vej 3, 2200 København N
Ny kommune: København
Vedtægter ændret: 06.11.2025
Kapitalforhøjelsen er besluttet den 06.11.2025.
kr. 2.000,00, indbetalt kontant, kurs 7.500,00.
Kapitalen udgør herefter kr. 63.300,00.
Vedtægter ændret: 01.05.2025
Kapitalforhøjelsen er besluttet den 01.05.2025.
kr. 6.000,00, indbetalt kontant, kurs 8.333,33.
Kapitalen udgør herefter kr. 61.300,00.
Vedtægter ændret: 18.11.2024
Kapitalforhøjelsen er besluttet den 18.11.2024.
kr. 3.500,00, indbetalt kontant, kurs 14.285,71.
Kapitalen udgør herefter kr. 55.300,00.
Vedtægter ændret: 25.06.2024
Kapitalforhøjelsen er besluttet den 25.06.2024.
kr. 6.200,00, indbetalt kontant, kurs 16.129,03.
Kapitalen udgør herefter kr. 51.800,00.
Ny adresse: Diplomvej 381, 2800 Kongens Lyngby
Vedtægter ændret: 29.09.2023
Kapitalforhøjelsen er besluttet den 29.09.2023.
kr. 5.600,00, indbetalt kontant, kurs 35.714,29.
Kapitalen udgør herefter kr. 45.600,00.
Binavne: Combotope ApS, Sweetspot Therapeutics ApS.
Stiftelsesdato: 14.09.2023.
Virkningsdato: 14.09.2023.
Seneste vedtægtsdato: 14.09.2023.
Kapital:
kr. 40.000,00.
Kapitalklasser: Nej
Indbetalingsmåde: Indbetalt kontant kr. 40.000,00 til kurs 100,00, fuldt indbetalt.
Stiftere:
CVR-NR. 35257918 MOLIOR HOLDING ApS, c/o Søren Jakobsen, Skovhegnet 5, 2920 Charlottenlund, den 14.09.2023, CVR-NR. 35408975 LAUSTSEN VENTURES ApS, c/o Laustsen, Lundtoftevej 153B, 2800 Kongens Lyngby, den 14.09.2023, CVR-NR. 44234882 Kolab Holding ApS, c/o Yen-Hsi Chen, Fadet 6, 24. 1, 1799 København V, den 14.09.2023.
Direktion:
Søren Nyboe Jakobsen, den 14.09.2023, Klas Ola Blixt, den 14.09.2023.
Selskabet tegnes af én direktør.
Første regnskabsår:
14.09.2023 - 31.12.2024.
Regnskabsår:
01.01 - 31.12.
Formål:
Selskabets formål er drive erhvervsmæssig virksomhed inden for service, handel og/eller produktion, samt enhver aktivitet, der står i forbindelse hermed.
P-number 1029645341Ole Maaløes Vej 3, 2200 København N
No other current company drawn.